



C-Rad will appeal the Patent and Market appeal court's ruling about compensation to a former employee to the Supreme Court.

C-Rad's board of directors has today decided to appeal and seek leave to appeal to the Supreme Court regarding the judgment issued by the Patent and Market Court of Appeal on 30 June 2023 where a former employee was awarded compensation for C-Rad's use of an invention. The appeal will be filed before 28 July 2023.

The Patent and Market Court of Appeal has granted permission to appeal the decision to the Supreme Court.

For further information:

Cecilia de Leeuw, CEO, +46 (0)18 751 33 22, investors@c-rad.com
Christoffer Herou, CFO, +46 (0)725 82 86 16, investors@c-rad.com

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

Attachments

[C-Rad will appeal the Patent and Market appeal court's ruling about compensation to a former employee to the Supreme Court.](#)